Real Money authors - Bret Jensen

Bret Jensen

Bret Jensen was chief investment strategist from 2008-2011 for Simplified Asset Management (S.A.M.), a small long/short hedge fund based in Miami. The fund was in top 5% of long/short hedge funds for total return in its first full year (2009) as ranked by Hedgeco fund database (more than 450 funds in category). Jensen has nearly 20 years of experience in the financial services industry, including more than a decade of managerial experience at American Express. He holds a Bachelor of Science degree in finance from Arizona State University. His personal blog is at Jensen acts as corporate secretary for Florida Alternative Investment Association, which encompasses more than 100 managers managing more than $30 billion in assets under management. Follow Bret on Twitter: @Bret_Jensen.
Email Bret Jensen

Recent Articles By The Author

3 Covid-Proof Plays Not Named Amazon or Apple

Tutor Perini, Beazer Homes and Alexion Pharmaceuticals all turned in solid results in the face of the pandemic.

4 Financial Names That Offer Value in a Market Where It's Tough to Find

These companies are trading at reasonable multiples and two are offering nice dividend yields, too.

I Find Little Energy for Most of the Market

I'm looking for some financial names that still offer value in a very uncertain market.

Corbus Pharmaceuticals Is an Example of How I'm Playing an Uncertain Market

CRBP has topline Phase 3 data for its primary compound Lenabasum for Systemic Sclerosis due out this summer.

Indices Look Susceptible to a Pullback, and a Way to Play a Dinged Biopharma

Various hard-charging mega-cap stocks seem overdue for a significant pause, while a drop in Acadia Pharmaceuticals sets up an options play.

A Few Positives on the Covid-19 Front and a Biotech Stock to Consider

The biotech is Paratek Pharmaceuticals and it presents itself as a good covered call play.

3 Short-Term Threats to Increasingly Complacent Holders of Equities

The market seems to be overlooking this trio of potential setbacks to stocks.

Playing Small Ball With 2 Biotechs

This is why I continue to employ covered calls almost exclusively to put new 'ammo' to work targeting special situations.

Time to Batten Down the Hatches Before Possible Storms Ahead

Concerns over the strength of the recovery in the jobs market and the rate of Covid-19 cases are reasons for caution despite a resurgent market.

Prepare for a Critical Few Weeks Ahead

Discretion could be the better part of valor with the markets trading at current levels and uncertainty still surrounding Covid-19 and the job market.

Email sent

Thank you, your email to has been sent successfully.


We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight